DelveInsight’s Iron Overload Syndrome Market Insights Report offers a detailed analysis of disease, its causes, symptoms, diagnostics modalities, and treatment options.
The Iron Overload Syndrome market report also offers comprehensive insights into the Iron Overload Syndrome market size, epidemiology, emerging therapies, market drivers, market barriers, ongoing clinical trials, key collaboration in the space, and key pharmaceutical companies actively pushing iron overload syndrome market size growth forward.
Some of the key highlights from the Iron Overload Syndrome Market Insights:
- According to Crooks et al. (2008), the total hemochromatosis prevalence in the United Kingdom increased by two-fold throughout the decade, from 3.62 to 7.8 per 100 000 people. The age range 40–69 was the most common, accounting for 64 percent of all hemochromatosis cases.
- Major players such as Protagonist Therapeutics, Inc., AbFero Pharmaceuticals, Novartis Pharmaceuticals, and others are developing therapies for the treatment and management of Iron overload syndrome. These therapies are currently under different stages of development.
- Key pipeline therapies in the Iron overload syndrome market include PTG-300, SP-420, Exjade, among others.
Learn more by requesting for sample @ Iron Overload Syndrome Market Landscape
Iron Overload Syndrome: Overview
Iron is required for cell metabolism and the production of hemoglobin, myoglobin, and cytochrome P450, among other hemoproteins. As a result, under normal physiologic settings, total body iron levels are carefully regulated. Iron overload can be inherited (genetic) or acquired through many blood transfusions, iron shots or injections, or additional iron consumption.
Hereditary hemochromatosis (all types), African iron overload, sickle cell disease, thalassemia, X-linked sideroblastic anemia, enzyme deficiencies (pyruvate kinase; glucose-6-phosphate dehydrogenase), and sporadic protein transport disorders aceruloplasminemia and atransferrinemia are some of the genetic disorders that cause iron overload syndrome.
For more insights into disease, causes, and treatment, reach out to Iron Overload Syndrome Treatment Landscape.
Iron Overload Syndrome Epidemiology Segmentation
The Iron Overload Syndrome Market report proffers epidemiological analysis for the study period 2017-30 in the 7MM segmented into:
- Iron Overload Syndrome Prevalence
- Age-Specific Iron Overload Syndrome Prevalence
- Gender-Specific Iron Overload Syndrome Prevalence
- Diagnosed and Treatable Cases of Iron Overload Syndrome
Visit for more @ Iron Overload Syndrome Epidemiological Insights.
Iron Overload Syndrome Market
An increase in the number of cases of iron overload syndrome, along with the expected approval of emerging therapies will boost the iron overload syndrome market in the forecasted period [2021-2030]. The iron overload syndrome pipeline brings a positive ray of hope for a better treatment pattern in the market in the upcoming years. The current scenario also anticipates a positive shift in the market.
PTG-300 is the most anticipated emerging therapy that is awaiting approval. Another treatment, Exjade (Deferasirox), is being evaluated in a phase II trial in patients with HH, which was previously approved to treat chronic iron overload due to blood transfusions.
Iron Overload Syndrome Pipeline Therapies and Key Companies
- PTG-300: Protagonist Therapeutics, Inc.
- SP-420: AbFero Pharmaceuticals
- Exjade: Novartis Pharmaceuticals
For more information, visit Iron Overload Syndrome Market Analysis, Patient Pool, and Emerging Therapies.
Iron Overload Syndrome Market Drivers
- Rising prevalent population
- Technological advancements
- Emerging therapies
- Extensive R&D
Scope of the Report
- 11 Years Forecast
- 7MM Coverage
- Descriptive overview of Iron Overload Syndrome, covering causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
- Comprehensive insight into Iron Overload Syndrome epidemiology and treatment in the 7MM
- Iron Overload Syndrome current and emerging therapies
- Iron Overload Syndrome market drivers and barriers
Key Questions Answered in the Report:
- What was the Iron Overload Syndrome market share (percentage) distribution in 2017, and how would it appear in 2030?
- What is the total Iron overload syndrome market size and the market size by therapy across the 7MM for the projected period (2017-2030)?
- What are the important findings from 7MM, and which country will have the greatest Iron Overload Syndrome market size from 2017 to 2030?
- During the projection period (2017-2030), at what CAGR is the Iron Overload Syndrome market projected to expand at 7MM?
Get in touch with our Business executive @ Iron Overload Syndrome Market Landscape Analysis.
Table of Contents:
| 1. | Key Insights |
| 2. | Report Introduction |
| 3. | Competitive Intelligence Analysis for Iron Overload Syndrome |
| 4. | Iron Overload Syndrome Market Overview at a Glance |
| 5. | Executive Summary of Iron Overload Syndrome |
| 6. | Iron Overload Syndrome Epidemiology and Market Methodology |
| 7. | Iron Overload Syndrome Epidemiology and Patient Population |
| 8. | Iron Overload Syndrome Patient Journey |
| 9. | Treatment Algorithm, Current Treatment, and Medical Practices |
| 10. | Key Endpoints in Iron Overload Syndrome Clinical Trials |
| 11. | Iron Overload Syndrome Marketed Therapies |
| 12. | Iron Overload Syndrome Emerging Therapies |
| 13. | Iron Overload Syndrome: 7 Major Market Analysis |
| 14. | Attribute analysis |
| 15. | Access and Reimbursement Overview of Iron Overload Syndrome |
| 16. | KOL Reviews |
| 17. | Case Reports |
| 18. | Iron Overload Syndrome Market Drivers |
| 19. | Iron Overload Syndrome Market Barriers |
| 20. | SWOT Analysis |
| 21. | Disclaimer |
| 22. | DelveInsight Capabilities |
| 23. | About DelveInsight |
Learn more about the report offerings @ Iron Overload Syndrome Market Outlook
Related Reports:
Iron Overload Syndrome Epidemiology
DelveInsight’s ‘Iron Overload Syndrome – Epidemiology Forecast to 2030’ report.
Latest Reports:
Intrahepatic Cholangiocarcinoma (ICCA) Market
DelveInsight’s ‘Intrahepatic Cholangiocarcinoma (ICCA) – Market Insights, Epidemiology, and Market Forecast–2030’ report.
COVID 19 Therapeutic Pipeline, Vaccines, and Diagnostics Competitive Landscape, 2020
DelveInsight’s ‘COVID 19 (Novel Coronavirus 19) Therapeutic Pipeline, Vaccines, and Diagnostics Competitive Landscape, 2020’ report.
DelveInsight’s “Cervical Dysplasia – Market Insights, Epidemiology, and Market Forecast-2030” report.
DelveInsight’s “Agoraphobia – Market Insights, Epidemiology, and Market Forecast-2030” report.
DelveInsight’s “Hydrocephalus – Market Insights, Epidemiology, and Market Forecast-2030” report.
DelveInsight’s ‘Sarcopenia–Market Insights, Epidemiology, and Market Forecast-2030’ report.
Diabetic Kidney Disease Market
DelveInsight’s “Diabetic Kidney Disease (DKD) – Market Insights, Epidemiology, and Market Forecast-2030” report.
DelveInsight’s ‘Acromegaly-Market Insights, Epidemiology, and Market Forecast–2030’ report.
Acute Respiratory Distress Syndrome (ARDS) Market
DelveInsight’s ‘Acute Respiratory Distress Syndrome (ARDS) – Market Insights, Epidemiology and Market Forecast – 2030’ report.
Acute Kidney Injury (AKI) Market
DelveInsight’s ‘Acute Kidney Injury (AKI) – Market Insights, Epidemiology and Market Forecast– 2030’ report.
DelveInsight’s “Renal Anemia – Market Insights, Epidemiology, and Market Forecast-2030” report.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences providing end-to-end comprehensive solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Information:
Kritika Rehani info@delveinsight.com +1(919)321-6187
Tags:
Menafn, IPS, Reportedtimes, PR-Wirein, Extended Distribution, iCN Internal Distribution, Research Newswire, English
Contact Information:
Kritika Rehani
info@delveinsight.com
+1(919)321-6187